[Polyclonal CD8+/CD57+ T cell expansions: clinical significance]

Area of Science:

• Immunology
• Cellular Biology
• Clinical Medicine

Background:

• Polyclonal CD8(+)/CD57(+) T cell lymphocytosis arises from chronic antigen stimulation.
• These T cells exhibit features of terminal differentiation, including CD28 loss and CD57 expression, and reduced proliferation capacity.
• This T cell subset may display immunosenescence and altered cytotoxic functions, potentially acting as regulatory cells.

Purpose of the Study:

• To highlight the diagnostic and therapeutic significance of CD8(+)/CD57(+) T cell expansion.
• To emphasize the clinical utility of identifying this T cell population in specific patient groups.
• To underscore the potential for immunomodulatory therapies in managing conditions associated with this expansion.

Main Methods:

• Flow cytometry analysis to identify and quantify CD8(+)/CD57(+) T cells.
• Clinical correlation of T cell expansion with patient conditions such as organ infiltration and neutropenia.
• Evaluation of treatment responses to immunomodulatory therapies.

Main Results:

• CD8(+)/CD57(+) T cell expansion is associated with chronic viral infections, autoimmune diseases, and immune deficiencies.
• Patients with this expansion may present with organomegaly, organ infiltration, or unexplained neutropenia.
• Identification of CD8(+)/CD57(+) T cell expansion can predict favorable responses to immunomodulatory treatments.

Conclusions:

• CD8(+)/CD57(+) T cell expansion is a valuable diagnostic marker for various clinical conditions.
• Its presence suggests potential therapeutic benefits from immunomodulatory interventions, particularly in cases of organ infiltration or neutropenia.
• Further research is warranted to fully elucidate the clinical implications and therapeutic potential of this T cell subset.